You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Polyionic Papillomavirus like Particles VLP for the Treatment of HPV oropharyngeal squamous cell carcinomas OPCs

    SBC: PATHOVAX LLC            Topic: 102

    The broader impact commercial potential of PathoVax s STTR phase I proposal is to improve outcomes of cancer immuno therapy utilizing a vaccine formulation combining an immunogenic chimeric virus like particle cVLP vaccine with FDA approved immune check point inhibitors PathoVax proposes to develop this technology for treatment of human papillomavirus HPV associated cancers However cancer ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction

    SBC: MOLECULAR EXPRESS, INC            Topic: R42

    DESCRIPTION provided by applicant Heroin and related opioids are highly addictive drugs known for their analgesic properties Since the number of heroin users in the United States has skyrocketed reaching epidemic levels Abuse of prescription opioid pain relievers oxycodone Oxycotin and hydrocodone Vicodin which are known gateway drugs to heroin has also increased dramatically Beca ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Pre-clinical Development of a Vaccine for the Treatment of Heroin Addiction

    SBC: MOLECULAR EXPRESS, INC            Topic: R42

    DESCRIPTION provided by applicant Heroin and related opioids are highly addictive drugs known for their analgesic properties Since the number of heroin users in the United States has skyrocketed reaching epidemic levels Abuse of prescription opioid pain relievers oxycodone Oxycotin and hydrocodone Vicodin which are known gateway drugs to heroin has also increased dramatically Beca ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Pre-clinical evaluation of DT-001, a small molecule antagonist of MD2-TLR4 for utility in the treatment of pain.

    SBC: Douleur Therapeutics Inc            Topic: NINDS

    Project Summary AbstractUpwards ofmillion individuals are afflicted by chronic pain in the US alonewithmillion of these individuals suffering from neuropathic painOn a global scalechronic pain affectsbillion individualswithwho endure lower back painFrom a clinical perspectivethe International Association for the Study of Pain approximates thatinpatients present with painand on an annual basisinpat ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Preclinical Testing of a Novel Flow Diverting Stent for Treating Intracranial Aneurysms

    SBC: NeuroSigma, Inc.            Topic: 101

    DESCRIPTIONprovided by applicantThe purpose of this project is to develop an improvedminimally invasive treatment for intracranial aneurysmsIntracranial aneurysms are spherical outpouchings of blood vessels in the head that result from weakness in the vessel wallUnruptured aneurysms are present in approximatelyof the general populationand rupture can be devastating with a high morbidity and mortal ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke

    SBC: TRANSLATIONAL SCIENCES INC.            Topic: NHLBI

    Seventeen million people each year suffer from an ischemic stroke and millions are left dead and disabledTreatment with recombinant tissue plasminogen activatorr tPAis only modestly effective at reducing disability and it is associated with brain hemorrhage in up toof patients when serial imaging studies are performedBrain hemorrhage causes death and disability andis the major cause of early morta ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Production of Chemical Reagents for Prompt-Agent-Defeat Weapons

    SBC: NALAS ENGINEERING SERVICES INC            Topic: DTRA14B001

    The US DoD requires robust ways of neutralizing threats posed by hostile powers and terrorist organizations that may be in possession of dangerous weapons of mass destruction (WMDs). Unfortunately, the weapons currently available to the DoD do not offer a way for the WMD to be destroyed without risking the spread of that material throughout the area. The strategy for the defeat of biological weapo ...

    STTR Phase I 2015 Department of DefenseDefense Threat Reduction Agency
  8. Production of Chemical Reagents for Prompt-Agent-Defeat Weapons

    SBC: NALAS ENGINEERING SERVICES INC            Topic: DTRA14B001

    Nalas Engineering and Johns Hopkins University collaborated in a Phase I STTR program to study reactive mixtures of HI3O8 and nanocomposite fuels previously developed by the Weihs Group. These fuel/oxidizer mixtures are uniquely able to simultaneously produce heat and biocidal iodine gas, a combination designed to destroy biological weapons. The team at Nalas focused on evaluating conditions for p ...

    STTR Phase II 2017 Department of DefenseDefense Threat Reduction Agency
  9. Production of Inactivated Vaccines Using Supralethal Irradiation

    SBC: BIOLOGICAL MIMETICS, INC.            Topic: DTRA14B002

    The discovery and commercial development of licensed vaccines often take many years of research followed by years of pre-clinical and clinical development. We propose to assess the feasibility of using a novel irradiation-inactivation technology to develop vaccines more rapidly. The technology utilizes a manganese-peptide complex to protect antigenic proteins from ionizing radiation while allowing ...

    STTR Phase II 2017 Department of DefenseDefense Threat Reduction Agency
  10. Production of Inactivated Virus Vaccines Using Supralethal Irradiation

    SBC: BIOLOGICAL MIMETICS, INC.            Topic: DTRA14B002

    We seek a proof-of-concept study for the development of a new platform technology for the rapid and complete inactivation of pathogen infectivity for vaccine development of medically important micro-organisms (e.g. viruses, bacteria and parasites). A recently discovered reconstituted Mn+2-decapeptide phosphate complex (Mn-Dp-Pi) of the radiation-resistant bacterium Deinococcus radiodurans was foun ...

    STTR Phase I 2015 Department of DefenseDefense Threat Reduction Agency
US Flag An Official Website of the United States Government